mAbxience

mAbxience is a global, vertically integrated biotech firm with a dual focus on developing its own portfolio of biosimilar monoclonal antibodies and offering comprehensive CDMO services. With over a decade of experience, it operates state-of-the-art GMP manufacturing facilities in Europe and South America, boasting a combined cell culture capacity of 50,000L. The company leverages its in-house R&D expertise to improve patient access to high-quality biologics worldwide, recently achieving significant regulatory milestones like FDA approval for denosumab biosimilars.

Vertically integrated biologics development and manufacturing platform specializing in biosimilar monoclonal antibodies. Utilizes single-use bioreactor technology across multiple GMP facilities with 50,000L total capacity, supporting end-to-end services from R&D to commercial production. Investing in AI for biomanufacturing optimization.

Operates in the highly competitive biosimilar development space against large generics firms (e.g., Sandoz, Biocon) and biotech specialists. As a CDMO, it competes with established players like Lonza, Samsung Biologics, and Fujifilm Diosynth, where scale, technology, and cost are key differentiators.